PG490-88

11/27/2000 - "PG490-88 was administrated into recipient mice in a model (B10.D2-->BALB/c) of lethal graft-versus-host disease (GVHD) to study the effects of PG490-88 on GVHD and on the various steps involved in the pathological course of GVHD. "
11/27/2000 - "Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion."
01/15/2002 - "PG490-88, a semisynthetic derivative of a novel compound PG490 (triptolide) purified from a Chinese herb (Tripterygium wilfordii Hook F), is effective in prevention of murine graft-versus-host disease (GVHD). "

03/01/2001 - "The efficacy of PG490-88 when administered late after bleomycin installation suggests a potential role in the treatment of idiopathic pulmonary fibrosis."

09/01/2003 - "A phase I trial of PG490-88 for solid tumors began recently and safety and optimal dosing data should accrue within the next 12 months. "
09/01/2003 - "We show that PG490-88 is a safe and potent antitumor agent when used alone, causing tumor regression of lung and colon tumor xenografts. "
09/01/2003 - "Our findings that PG490-88 causes tumor regression and that it acts in synergy with DNA-damaging chemotherapeutic agents suggest a role as an antineoplastic agent and chemosensitizer for the treatment of patients with solid tumors."
09/01/2003 - "We also show that PG490-88 acts in synergy with CPT-11 to cause tumor regression. "
09/01/2003 - "PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy."

06/01/2014 - "The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury."

03/01/2011 - "Importantly, PG490-88 has been approved entry into Phase I clinical trial for treatment of prostate cancer in USA. "